Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.61
-0.0100-0.62%
Post-market: 1.60-0.0096-0.60%19:59 EDT
Volume:6.74M
Turnover:9.67M
Market Cap:36.49M
PE:-0.12
High:1.61
Open:1.50
Low:1.24
Close:1.62
52wk High:10.99
52wk Low:1.24
Shares:22.66M
Float Shares:15.77M
Volume Ratio:8.47
T/O Rate:42.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.11
PE(LYR):-0.09

Loading ...

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 06

Karyopharm Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $13 From $8

THOMSON REUTERS
·
May 06

Karyopharm files to sell 8.84M shares of common stock for holders

TIPRANKS
·
May 05

BRIEF-Karyopharm Therapeutics May Offer Up To $400 Million In Securities - SEC Filing

Reuters
·
May 05

Karyopharm Therapeutics Inc - May Offer up to $400 Mln in Securities - SEC Filing

THOMSON REUTERS
·
May 05

Karyopharm Therapeutics Price Target Raised to $16.00/Share From $8.00 by Piper Sandler

Dow Jones
·
Apr 28

Karyopharm price target raised to $16 from $8 at Piper Sandler

TIPRANKS
·
Apr 27

U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global

Reuters
·
Apr 27

Karyopharm Therapeutics Inc : Piper Sandler Raises Target Price to $16 From $8

THOMSON REUTERS
·
Apr 27

Karyopharm Phase 3 SENTRY myelofibrosis trial results set for ASCO late-breaking oral presentation

Reuters
·
Apr 21

Karyopharm publishes corporate presentation highlighting Phase 3 selinexor readouts in myelofibrosis

Reuters
·
Apr 16

RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler

Dow Jones
·
Mar 31

Karyopharm Therapeutics Inc : Piper Sandler Cuts Target Price to $8 From $12

THOMSON REUTERS
·
Mar 30

Karyopharm Therapeutics sells 1,030,354 shares at $6.785; gross proceeds rise to about $30 million in RA Capital private placement

Reuters
·
Mar 27

BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds

Reuters
·
Mar 25

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 25

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Benzinga
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24